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Elevated troponin levels in acute stroke are negatively 
associated with outcome at 3 months.
CL McVeigh¹, AP Passmore¹, A McSorley², M Power², D 
Gilmore³,  I  Steele³, TRO  Beringer³,  MI Wiggam¹.  Stroke 
unit,  Belfast  City  Hospital¹,  Stroke  unit,  Ulster  Hospital 
Dundonald², Stroke unit, Royal Victoria Hospital³. Belfast.  





























Contemporory management of acute coronary 
syndromes: insights from the Mater hospital cardiology 
database
V  Kodoth,  J  Hastings,  B  McClements.  Department  of 
Cardiology, Mater Hospital, Crumlin Road, Belfast
Background:  Management  of  acute  coronary  syndrome 
(ACS)  has  changed  significantly  in  recent  years.  Current 
guidelines advise early inpatient coronary angiography for 
many patients. We reviewed the Mater Hospital cardiology 





a  database. This  was  analysed  for  the  period April  2005 
to  September  2006.  Of  598  patients  with  acute  coronary 
syndrome, 100 (17%) had ST elevation myocardial infarction 
(STEMI),  133  (22%)  had  NON-STEMI  and  365  (61%) 










STEMI  patients  and  9/133  (8%)  NON-STEMI  patients 
underwent exercise treadmill testing prior to discharge. Rates 
of  prescription  of  evidence-based  secondary  prevention 
medications for the whole study population were:  aspirin 
502/598  (84%),  clopidogrel  434/598  (73%),  beta-blocker 








for  unselected  patients  with  STEMI  remains  significant.   
A large proportion of ACS patients, and particularly those 
with  STEMI  and  NON-STEMI,  have  inpatient  coronary 
angiography  and  subsequent  revascularisation  procedures.   




Pseudo-hyperkalaemia and aetiology of thrombocytosis: 
a six-year retrospective correlation study
R  Deore,  S  Harte,  MJ  Bowers,  M  El-Agnaf, YL  Ong.   
Department  of  Haematology,  Ulster  Hospital  Dundonald, 
Belfast BT16 1RH
Pseudohyperkalaemia is a rarely encountered event among 
patients  with  thrombocytosis.  Typically,  a  raised  serum 
potassium level is observed in the absence of renal failure, 
and  it  causes  unnecessary  anxiety  among  clinicians. 
Pseudohyperkalemia may lead to inappropriate administration 
of  calcium  resornium,  insulin  in  5%  dextrose  in  an 
attempt to lower potassium level. The association between 
pseudohyperkalaemia  and  aetiology  of  thrombocytosis  is 
unclear.









the  upper  limit  of  the  normal  range  (K>5  mmol/l)  was 
observed  in  the  majority  of  patients  with  thrombocytosis 
from any aetiology (66.6%, n=60). The likelihood of finding 
pseudohyperkalaemia  was  highest  among  patients  with 
primary  thrombocythaemia  (91.4%,  n=32/35),  followed 
by  polythaemia  rubra  vera  (56%,  n=9/16),  and  reactive ©  The Ulster Medical Society, 2007.
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Systematic review: blood pressure lowering in patients 
without prior cerebrovascular disease for prevention of 
cognitive impairment and dementia
B McGuinness, S Todd, R Bullock, AP Passmore. Department 
of  Geriatric  Medicine,  Queens  University  Belfast, Whitla 
Medical Building, Lisburn Road, Belfast.
Hypertension and cognitive impairment are prevalent in older 
people.  Hypertension  is  a  known  risk  factor  for  vascular 







to  lower  blood  pressure  (BP)  were  administered  for  ≥  6 












Results of cognitive change from baseline outcome: No 
significant benefit from treatment (WMD=0.10, 95% CI -
0.03, 0.23).
Conclusion:  there  was  no  convincing  evidence  that  BP 




active  treatment  and  loss  to  follow-up.  Further  placebo-
controlled trails would be necessary but this raises ethical 
issues.
An unusual cause of abnormal thyroid function tests
EM Mackay1, S Mamanasiri2, AB Atkinson1, B Sheridan1, S 
Refetoff2,3, CH Courtney.1  1Regional Centre for Endocrinology 
and  Diabetes,  Royal  Victoria  Hospital,  Departments  of 
2Medicine, 3Pediatrics and Committee on Genetics University 
of Chicago, Chicago, IL, USA













on  chromosome  3,  revealed  a  point  mutation  at  position 
460 with substitution of the normal glutamic acid by lysine 







RTH  is  a  condition  of  impaired  tissue  responsiveness  to 
thyroid hormone.  The more common forms are caused by 
TRβ gene mutations and inherited in a dominant fashion.  Of 
the 170 different TRβ mutations, E460K has been identified 
in three other families.  This mutation reduces the affinity of 
TRβ for T3 to 25% that of the normal receptor.  RTH should 
be considered in patients presenting with elevated FT4 and 
unsuppressed TSH. Its identification prevents unnecessary 
investigation and inappropriate treatment in the patient and 
in other affected family members.
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